The Centers for Disease Control and Prevention Starting this fall, the CDC is recommending the respiratory syncytial virus (RSV) vaccine to help protect all infants younger than 8 months and some older infants at higher risk for severe illness.
CDC Director Mandy Cohen adopted the ACIP's Advisory Committee on Immunization Practices (ACIP) recommendation for use of nirsevimab, brand name BeyfortusTM, a long-acting monoclonal antibody product that has been shown to reduce the risk of hospitalization and health care visits due to RSV in infants by approximately 80 percent.
Antibodies are part of our immune system and help us fight infections. However, monoclonal antibodies are proteins made by humans that mimic the antibodies our bodies produce naturally.